Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS

Author(s): Charikleia Christakou, Evanthia Diamanti-Kandarakis

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 32 , 2013

Become EABM
Become Reviewer
Call for Editor


Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.

Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 July, 2013
Page: [5764 - 5774]
Pages: 11
DOI: 10.2174/1381612811319320011
Price: $65

Article Metrics

PDF: 28